Benjamin H. Rajewski

Benjamin H. Rajewski

Auto-generated profile, based on publicly available information

Benjamin H. Rajewski

Endevica Bio, Northbrook, IL, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
RZRunyao Zhu
Runyao Zhu
KMKamlesh M. Makwana
Kamlesh M. Makwana
YZYouwen Zhang
Youwen Zhang
BRBenjamin H. Rajewski
Benjamin H. Rajewski
JVJuan Del Valle
Juan Del Valle
YWYichun Wang
Yichun Wang
Graphene quantum dots with engineered properties are able to block the seeding activity of tau fibrils by inhibiting the fibrillization of monomeric tau and triggering the disaggregation of tau filaments.

29 May 2026 in Nature Communications
Verified
Journal Article
Open access
JSJillian L. Seiler
Jillian L. Seiler
AIAnna C. Impastato
Anna C. Impastato
EZEmma Xiaoyu Zhang
Emma Xiaoyu Zhang
KKKade J. Kelley
Kade J. Kelley
TBThomas L. Bennett
Thomas L. Bennett
DMdaniel marks
daniel marks
The melanocortin system plays a central role in regulating hunger and satiety, making it an attractive target for treating metabolic disease. However, the limited clinical success of selective melanocortin-4 receptor (MC4R) agonists has prompted investigation into whether concurrent melanocortin-3 receptor (MC3R) and MC4R activation may more effectively engage this pathway for the treatment of general obesity. Here we show that selective MC3R agonism modulates food intake in a state-dependent manner, and that co-agonism of MC3R and MC4R produces greater metabolic effects than selective MC4R agonism alone, consistent with non-redundant and cooperative roles. Using novel peptides in male nonhuman primates and rodents, we develop 710GO, an orally available MC3R/MC4R dual agonist that induces significant weight loss in primates with diet-induced obesity. Oral 710GO demonstrates limited weight rebound, compatibility with GLP-1-based therapies, and a favorable preclinical safety profile. These findings support combined MC3R/MC4R agonism as a promising approach for next-generation obesity therapeutics.

29 November 2025 in bioRxiv
Verified
Preprint
Open access
JSJillian L Seiler
Jillian L Seiler
AIAnna C Impastato
Anna C Impastato
EZEmma (Xiaoyu) Zhang
Emma (Xiaoyu) Zhang
KKKade J Kelley
Kade J Kelley
TBThomas L Bennett
Thomas L Bennett
DMDaniel L Marks
Daniel L Marks
The melanocortin system plays a central role in regulating hunger and satiety, making it an attractive target for treating metabolic disease. However, the limited clinical success of selective melanocortin-4 receptor (MC4R) agonists prompted the investigation of whether concurrent melanocortin-3 receptor (MC3R) and MC4R activation is key to unlocking the melanocortin system for the treatment of general obesity. To test this hypothesis, we designed and synthesized novel peptides to probe the distinct and combined roles of MC3R and MC4R in nonhuman primates (NHPs). We show that selectively agonizing MC3R modulates food intake in a state-dependent manner. Moreover, co-agonism of MC3R and MC4R results in more substantial metabolic effects than selective MC4R agonism, highlighting both a non-redundant and a cooperative role of MC3R. To leverage these discoveries, we developed 710GO, an orally-available MC3R/MC4R dual agonist peptide that induces significant weight loss in diet-induced obese (DIO) NHPs. Oral 710GO treatment demonstrates limited weight rebound, has additive effects in combination with GLP-1s, and exhibits a clean safety profile. These results reestablish the melanocortin system, specifically concerted MC3R/MC4R agonism, as a viable mechanism for next-generation obesity therapeutics.